Chief, Division of Leukemia, Department of Medicine
Professor of Medicine, School of Medicine & Biomedical Sciences, University at Buffalo
Assistant Research Professor, Department of Immunology
Immunology Program, Roswell Park Graduate Division

Roswell Park Cancer Institute
Elm and Carlton Streets
Buffalo, NY 14263 USA
Tel: 716-845-8447
Fax: 716-845-2343
E-mail: meir.wetzler@roswellpark.org

Current Program

• autocrine and paracrine growth factor regulatory loops in the pathogenesis of leukemia
• of signal transducer and activator of transcription (STAT) proteins in leukemogenesis

Profile

Dr. Meir Wetzler joined the staff of Roswell Park Cancer Institute (RPCI) in 1994, as Clinician, Division of Leukemia, Department of Medicine. He earned his medical degree from the Hebrew University Hadassah Medical School, Jerusalem, Israel, in 1980, and completed residency training in Internal Medicine at Kaplan Hospital (affiliated with Hebrew University Hadassah Medical School), Rehovot, Israel, in 1986. From 1988 to 1992, he completed fellowships in Clinical Immunology and Biologic Therapy, and in Medical Oncology at M.D. Anderson Cancer Center, Houston, TX.

Dr. Wetzler is licensed in New York, Texas and Israel. He also is Professor of Medicine, School of Medicine & Biomedical Sciences, University of Buffalo, Assistant Research Professor, Immunology Program, Roswell Park Graduate Division, and a member of the Adjunct Faculty, Physician Assistant Department, D’Youville College, Buffalo, NY.

Dr. Wetzler’s research interests focus on the role of signal transducer and activation of transcription in leukemogenesis; the cellular and humoral immune response to leukemic-associated antigens; and cytogenetics in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).

Dr. Wetzler is a member of the American Society of Clinical Oncology, American Association for Cancer Research, American Society of Hematology, and Israel Medical Association. Currently, he is a member of the Leukemia Core Committee, Cancer and Leukemia Group B, and the Chronic Myeloid Leukemia Treatment Committee, National Comprehensive Cancer Network. He has authored or co-authored more than 100 journal publications, book chapters and abstracts. He serves as Journal Referee for Blood, Cancer, Stem Cells, Leukemia Research, and the American Journal of Hematology.

Key Publications

• M. Wetzler, M.T. Brady, E. Tracy, Z.-R. Li, K.A. Donohue, K.L. O'Loughlin, Y. Cheng, A. Mortazavi, A.A. McDonald, P. Kunapuli, P.K. Wallace, M.R. Baer, J.K. Cowell, H. Baumann. Arsenic trioxide affects signal transducer and activator of transcription proteins through alteration of protein tyrosine kinase phosphorylation. Clin Cancer Res 12:6817-6825, 2006
• J.A. Claus, M.T. Brady, J. Lee, K.A. Donohue, S.N. Sait, S. Ferrone, M. Wetzler. T Cell Activation by t(9;22) Acute Lymphoblastic Leukemia-Derived Dendritic-Like Cells is Associated with Increased Tapasin Expression. Cancer Immunology and Immunotherapy 55:160-165, 2006
• M. Wetzler, R.K. Dodge, K. Mrózek, C.C. Stewart, A. Carroll, R.A. Larson, C.D. Bloomfield. The prognostic importance of secondary cytogenetic changes in adult acute lymphoblastic leukemia with t(9;22) – A Cancer and Leukemia Group B study. Br J Haematol, 124:275-288, 2004